Measuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes
Many patients with type 2 diabetes have difficulty attaining cholesterol goals, partly due to the recommendations for fasting measurements that may not be practical in the typical clinical setting. Focus toward therapy is shifting toward non-fasting assessments but little is known about the usefulness of this approach in diabetes, where postmeal cholesterol levels are more abnormal. This is an observational study examining fasting and postmeal lipids (cholesterol) in patients with type 2 diabetes using standard means and NMR.
Type 2 Diabetes
|Study Design:||Time Perspective: Prospective|
|Official Title:||A Comparison of NMR and Chemical Lipid Analysis in the Fasting and Postprandial State in Patients With Type 2 Diabetes|
|Study Start Date:||October 2005|
|Estimated Study Completion Date:||September 2006|
Current treatment guidelines for dyslipidemia focus on fasting lipid panels, specifically LDL cholesterol (LDL) but compliance has been shown to be poor. Therefore, focus has shifted to non-fasting measurements. However, there has been limited data in patients with type 2 diabetes and further study is needed to illuminate the lipid changes that occur in the non-fasting state. This observational study examines fasting and postprandial lipids in patients with type 2 diabetes using standard chemical analysis and NMR. For comparison, lipid panels will be obtained at baseline and 3 hours following a standard meal in 30 patients with type 2 diabetes. These measurements will then be analyzed based on current ATP III guidelines. We will investigate the degree to which the postprandial assessments agree with the fasting assessments and the agreement between LDL and the two alternative measures --- non-HDL and NMR-LDL.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00287404
|United States, North Carolina|
|University of North Carolina Diabetes Care Center|
|Durham, North Carolina, United States, 27713|
|Principal Investigator:||John Buse, MD, PhD||University of North Carolina, Chapel Hill|